Clinical Trial: A single-arm study on the efficacy and safety of SOX plus tislelizumab as neoadjuvant therapy for locally advanced gastric cancer (China)

Posted On: 2026-08-10

China, Aug. 10 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A single-arm study on the efficacy and safety of SOX plus tislelizumab as neoadjuvant therapy for locally advanced gastric cancer'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600129670

Registration Time: 2026/08/07

Type: Interventional study

Primary Sponsor: The First Affiliated Hospital of Army Medical University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=335061

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: A single-arm study on the efficacy and safety of SOX plus tislelizumab as neoadjuvant therapy for locally advanced gastric cancer (China)